Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of a nasal steroid and ketamine**, formulated for intranasal administration. Nasal steroids, commonly referred to as intranasal corticosteroids, are used as anti-inflammatory agents to treat allergic rhinitis and other nasal inflammatory conditions. **Ketamine** is an NMDA (N-methyl-D-aspartate) receptor antagonist, primarily used for its anesthetic, analgesic, antidepressant, and anti-inflammatory effects. Compounded products combining these agents are not FDA-approved and are sometimes used off-label, particularly in psychiatric and pain medicine settings. Intranasal ketamine, alone or in combination with other ingredients such as corticosteroids, is sometimes compounded for rapid-onset antidepressant or analgesic purposes, but its safety, efficacy, and dosing are not well established and have been the subject of regulatory concern[1][2]. There is no standardized, FDA-approved product consisting of a nasal steroid plus ketamine; such combinations are only available as compounded pharmaceuticals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nasal steroid + ketamine.